Japan Tissue Engineering Co., Ltd. (7774.T)
JPY 460.0
(-2.54%)
JPY 460.0
(-2.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 144.5 Million JPY | 119.85% |
| 2022 | -728.11 Million JPY | -46.16% |
| 2021 | -498.18 Million JPY | -6.71% |
| 2020 | -466.86 Million JPY | -98.51% |
| 2019 | -235.17 Million JPY | 32.76% |
| 2018 | -349.74 Million JPY | -265.36% |
| 2017 | 211.5 Million JPY | -32.29% |
| 2016 | 312.38 Million JPY | 143.23% |
| 2015 | -722.59 Million JPY | 20.86% |
| 2014 | -913.09 Million JPY | 10.95% |
| 2013 | -1.02 Billion JPY | 7.04% |
| 2012 | -1.1 Billion JPY | -26.76% |
| 2011 | -870.15 Million JPY | 4.42% |
| 2010 | -910.4 Million JPY | -0.27% |
| 2009 | -907.98 Million JPY | 1.6% |
| 2008 | -922.78 Million JPY | -12.23% |
| 2007 | -822.19 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -193.25 Million JPY | -183.36% |
| 2024 Q2 | -14.07 Million JPY | 92.72% |
| 2023 Q1 | 14.21 Million JPY | 113.71% |
| 2023 Q2 | -25.06 Million JPY | -276.36% |
| 2023 FY | 144.5 Million JPY | 119.85% |
| 2023 Q3 | -40.81 Million JPY | -62.85% |
| 2023 Q4 | 231.82 Million JPY | 667.96% |
| 2022 FY | -728.11 Million JPY | -46.16% |
| 2022 Q1 | -267.09 Million JPY | -68.47% |
| 2022 Q2 | -152.91 Million JPY | 42.75% |
| 2022 Q3 | -204.45 Million JPY | -33.7% |
| 2022 Q4 | -103.65 Million JPY | 49.3% |
| 2021 Q2 | -138.19 Million JPY | -6.5% |
| 2021 FY | -498.18 Million JPY | -6.71% |
| 2021 Q1 | -129.76 Million JPY | -128.41% |
| 2021 Q3 | -71.68 Million JPY | 48.13% |
| 2021 Q4 | -158.53 Million JPY | -121.16% |
| 2020 Q3 | -137.77 Million JPY | -41.18% |
| 2020 Q2 | -97.58 Million JPY | 44.14% |
| 2020 Q1 | -174.69 Million JPY | -235.75% |
| 2020 FY | -466.86 Million JPY | -98.51% |
| 2020 Q4 | -56.81 Million JPY | 58.76% |
| 2019 FY | -235.17 Million JPY | 32.76% |
| 2019 Q3 | -92.06 Million JPY | -5.82% |
| 2019 Q2 | -87 Million JPY | 52.92% |
| 2019 Q1 | -184.79 Million JPY | -240.88% |
| 2019 Q4 | 128.68 Million JPY | 239.78% |
| 2018 Q3 | -57.81 Million JPY | -412.25% |
| 2018 FY | -349.74 Million JPY | -265.36% |
| 2018 Q1 | -441.61 Million JPY | -590.9% |
| 2018 Q2 | 18.51 Million JPY | 104.19% |
| 2018 Q4 | 131.17 Million JPY | 326.88% |
| 2017 Q3 | 36.64 Million JPY | -53.53% |
| 2017 Q2 | 78.86 Million JPY | 1207.49% |
| 2017 FY | 211.5 Million JPY | -32.29% |
| 2017 Q1 | 6.03 Million JPY | -98.82% |
| 2017 Q4 | 89.96 Million JPY | 145.47% |
| 2016 FY | 312.38 Million JPY | 143.23% |
| 2016 Q4 | 511.32 Million JPY | 1478.74% |
| 2016 Q3 | -37.08 Million JPY | 8.28% |
| 2016 Q2 | -40.43 Million JPY | 66.7% |
| 2016 Q1 | -121.41 Million JPY | -2672.83% |
| 2015 Q2 | -202.91 Million JPY | 13.61% |
| 2015 Q3 | -289.52 Million JPY | -42.68% |
| 2015 Q4 | 4.71 Million JPY | 101.63% |
| 2015 FY | -722.59 Million JPY | 20.86% |
| 2015 Q1 | -234.87 Million JPY | -53.69% |
| 2014 Q2 | -314.89 Million JPY | -48.72% |
| 2014 Q4 | -152.81 Million JPY | 34.59% |
| 2014 FY | -913.09 Million JPY | 10.95% |
| 2014 Q1 | -211.73 Million JPY | 24.57% |
| 2014 Q3 | -233.64 Million JPY | 25.8% |
| 2013 Q3 | -253.12 Million JPY | 6.56% |
| 2013 Q1 | -220.71 Million JPY | 18.14% |
| 2013 FY | -1.02 Billion JPY | 7.04% |
| 2013 Q4 | -280.7 Million JPY | -10.9% |
| 2013 Q2 | -270.89 Million JPY | -22.74% |
| 2012 Q1 | -301.85 Million JPY | -24.95% |
| 2012 FY | -1.1 Billion JPY | -26.76% |
| 2012 Q4 | -269.61 Million JPY | 2.59% |
| 2012 Q3 | -276.79 Million JPY | -15.07% |
| 2012 Q2 | -240.54 Million JPY | 20.31% |
| 2011 FY | -870.15 Million JPY | 4.42% |
| 2011 Q1 | -261.47 Million JPY | 0.42% |
| 2011 Q4 | -241.59 Million JPY | 13.46% |
| 2011 Q3 | -279.17 Million JPY | 4.05% |
| 2011 Q2 | -290.95 Million JPY | -11.28% |
| 2010 Q1 | -289.05 Million JPY | -215.53% |
| 2010 Q3 | -304.83 Million JPY | -13.33% |
| 2010 Q4 | -262.57 Million JPY | 13.86% |
| 2010 Q2 | -268.98 Million JPY | 6.94% |
| 2010 FY | -910.4 Million JPY | -0.27% |
| 2009 FY | -907.98 Million JPY | 1.6% |
| 2009 Q3 | -256.77 Million JPY | 1.7% |
| 2009 Q2 | -261.2 Million JPY | 12.46% |
| 2009 Q1 | -298.39 Million JPY | -271.51% |
| 2009 Q4 | -91.61 Million JPY | 64.32% |
| 2008 FY | -922.78 Million JPY | -12.23% |
| 2008 Q3 | -278.35 Million JPY | -0.37% |
| 2008 Q2 | -277.32 Million JPY | 3.3% |
| 2008 Q1 | -286.79 Million JPY | 0.0% |
| 2008 Q4 | -80.32 Million JPY | 71.14% |
| 2007 FY | -822.19 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 75.787% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 129.084% |
| GNI Group Ltd. | 13.1 Billion JPY | 98.898% |
| Linical Co., Ltd. | 725.72 Million JPY | 80.088% |
| Trans Genic Inc. | 89.43 Million JPY | -61.576% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 110.134% |
| Soiken Holdings Inc. | -610 Million JPY | 123.689% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 118.701% |
| AnGes, Inc. | -11.96 Billion JPY | 101.207% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 112.893% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 101.517% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | -38.551% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 116.717% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 112.937% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 111.451% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 118.096% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 142.834% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 111.991% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 110.82% |
| PeptiDream Inc. | 6.77 Billion JPY | 97.866% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 107.487% |
| Ribomic Inc. | -1.11 Billion JPY | 112.946% |
| SanBio Company Limited | -4.53 Billion JPY | 103.184% |
| Healios K.K. | -3.37 Billion JPY | 104.277% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 112.511% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 110.37% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 110.3% |
| StemRIM | -2.07 Billion JPY | 106.961% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 88.17% |
| FunPep Company Limited | -994 Million JPY | 114.538% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 116.259% |
| Stella Pharma Corporation | -760.3 Million JPY | 119.007% |
| TMS Co., Ltd. | -943.25 Million JPY | 115.32% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 118.637% |
| Cuorips Inc. | -588.48 Million JPY | 124.556% |
| K Pharma,Inc. | 366.05 Million JPY | 60.523% |
| Takara Bio Inc. | 3 Billion JPY | 95.188% |
| ReproCELL Incorporated | -409.29 Million JPY | 135.306% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -1206.219% |
| StemCell Institute Inc. | 413.75 Million JPY | 65.075% |
| CellSeed Inc. | -697.77 Million JPY | 120.71% |